Summary
Immunovant's Chief Legal Officer executed a modest sell-to-cover transaction in early April as the company confronts disappointing Phase 3 results and a spectrum of analyst responses. The move fulfilled a tax obligation tied to the vesting of restricted stock units (RSUs) and took place against a backdrop of notable share-price appreciation over the past year.
Transaction details
According to a Form 4 filing with the Securities and Exchange Commission, Christopher Van Tuyl sold 5,165 shares of Immunovant common stock on April 8, 2026. The shares were sold at a weighted average price of $24.83 per share, with executed prices ranging from $24.54 to $25.39, resulting in total proceeds of $128,246.
Following the disposition, Van Tuyl continues to hold 183,231 shares of Immunovant stock directly. The filing states the sale was carried out to satisfy tax withholding obligations associated with the vesting and settlement of RSUs originally granted on April 1, 2025. Of those RSUs, 12,696 vested on April 1, 2026, and per company policy the resulting tax obligations were met through a mandatory "sell to cover" transaction.
Market context and valuation note
The transaction occurred while the stock has posted strong gains, trading up 66% over the past year and 44% in the last six months, according to InvestingPro data cited in the filing. InvestingPro analysis, referenced in the disclosure, also indicates the shares are overvalued relative to their Fair Value in that service’s assessment.
Clinical and analyst developments
Separately, Immunovant announced that its Phase 3 trials of batoclimab in thyroid eye disease did not meet the primary endpoint, which assessed proptosis response at 24 weeks. The failure to achieve the trial’s primary outcome prompted a range of analyst reactions.
Truist Securities reiterated a Hold rating and set a $23 price target, citing low expectations grounded in prior challenges seen in similar trials. Leerink Partners trimmed its price target to $50 from $52 but retained an Outperform rating. Oppenheimer kept an Outperform rating as well, with a $54 price target, highlighting the company’s next-generation drug candidate IMVT-1402 as a potential area of opportunity. Bernstein SocGen Group initiated coverage with a Market Perform rating and a $28 price target, placing a non-risk-adjusted value of $2.4 billion on the Graves’ disease program and valuing the Sjogren’s syndrome program at $2.0 billion with an assumed 70% success probability.
What this means
The insider sale was explicitly described as a tax-driven sell to cover following the vesting of RSUs, and the officer retained a substantial direct stake in the company. At the same time, the company is navigating a challenging clinical readout that has generated a mixed set of analyst judgments and updated price targets.
Disclosure
No additional disclosure was included in the regulatory filing beyond the transaction and its stated purpose.